MAP2K7 and melanoma: Involved in the RAS-MEK-ERK signalling pathway, BRAF is a serine/threonine kinase that lies downstream of RAS and has gained the most attention in malignant melanomas, where a V600E mutation is a common driver that is the therapeutic target of the selective BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) [27].